Revolutionary Cholesterol Pill Slashes Bad LDL by 60% in Major Clinical Trial
A groundbreaking new pill named enlicitide has significantly reduced “bad” LDL cholesterol levels by an estimated 60% in a comprehensive phase three clinical trial, equalling the effectiveness of injectable therapies currently available. These remarkable results, published in The New England Journal of Medicine on March 21, 2026, hold the potential to revolutionize heart disease prevention for millions of Americans.
The study, spearheaded by researchers at UT Southwestern Medical Center, put the experimental medication to the test on 2,909 patients. These individuals had either established atherosclerosis or were at a high risk of developing cardiovascular disease. After 24 weeks, participants who were administered enlicitide witnessed their LDL cholesterol plummet by as much as 60% in comparison to those given a placebo. These results remained consistent over a yearlong follow-up period.
“These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,” stated Dr. Ann Marie Navar, Associate Professor of Internal Medicine at UT Southwestern.
The pill operates by binding to the PCSK9 protein in the bloodstream, thereby enhancing the liver’s capacity to purge cholesterol from the blood.
What sets enlicitide apart is its oral delivery method. While injectable PCSK9 inhibitors are available and work similarly effectively, they are seldom prescribed due to their complexity and patients’ hesitation to use injections. If given the green light by the FDA, this once-daily pill could provide millions with a simpler route to managing their cholesterol levels and diminishing their risk of heart attacks and strokes. A separate clinical trial is already in progress to validate whether these cholesterol reductions directly result in fewer cardiovascular events.
Source: ScienceDaily